Clinical trial NCT01880840: Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR
Official title: Randomized Trial of the Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With Allergic Rhinitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Allergic Rhinitis
Lead sponsor: Meda Pharmaceuticals
Sponsor class: INDUSTRY
Collaborators: name: Novella Clinical
First posted: 2013-06-19
Enrollment: 191
Sex: ALL
Minimum age (years): 6
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the safety of 2 different doses of the investigational use of an allergy medication (Astepro Nasal Spray) in the treatment of allergic rhinitis (AR). This is an open-label study; that is, parent and child will know which group each is in.

Detailed description: Approximately 200 subjects, between the ages of ≥ 6 months to \< 6 years of age who have a history of AR will participate in this study.

The study will be conducted at about 20 research centers in the United States. Each research center will enroll approximately 2 to 10 subjects.

The study will involve at least 4 office visits over at least a 4-week period. You will need to keep the appointments as scheduled by the study personnel.

Some medications or therapies could interfere with the safety evaluations conducted in this study. If your child is currently taking any of these medications or therapies, they will need to discontinue them in order to be eligible for this study. Your study doctor will discuss this with you along with information on how this could affect your child's health. If you and the study doctor decide this is appropriate, there is a specific time period that these will need to be discontinued before your child can proceed in study evaluation.

If your child is eligible for study participation, he/she will be randomly assigned (by chance, like the flip of a coin) to one of the following two study drug groups:

* Astepro (azelastine hydrochloride) 0.15% Nasal Spray, 822 mcg (total daily dose); OR
* Astepro (azelastine hydrochloride) 0.1% Nasal Spray, 548 mcg (total daily dose)

The following are being performed for the purposes of this study and are not considered standard care:

* Your child will be placed in one of the two study drug groups by chance.
* You will complete questionnaires about your child's allergy symptoms.
* You will complete diary cards each morning recording your child's allergy symptoms over the previous 24 hours.
* Your child will have his/her vital signs measured (blood pressure, pulse, temperature and breathing rate).
* You and your child will be asked questions regarding your child's use of any medication or supplements and how your child has felt since his/her last visit.
* Blood and urine samples will be collected to assess the safety of taking the study drug.

Eligibility criteria: Inclusion Criteria:

* Male and female subjects \>6 months to \<6 years, inclusive at the screening visit
* A history of AR
* The parent must provide written informed consent and the child must provide assent, if possible
* Willing and able to comply with the study requirements
* May benefit from treatment with Astepro Nasal Spray, based on the Investigator's assessment (based on medical history, physical examination, etc.) of the subject's clinical condition, at both the Screening and Randomization Visits
* General good health and free of any disease or concomitant treatment that could interfere with the interpretation of the study results as determined by the investigator or the sponsor's medical officer
* Subjects receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit (adjustments to regimen following a brief period of missed injections do not preclude participation)

Exclusion Criteria:

* On nasal examination, subjects with superficial nasal mucosal erosion, moderate nasal mucosal erosion, nasal mucosal ulceration, nasal septum perforation
* Other nasal disease(s) likely to affect deposition of intranasal medication, such as acute sinusitis, rhinitis medicamentosa or clinically significant polyposis or nasal structural abnormalities
* Nasal surgery or sinus surgery within the previous year
* Chronic sinusitis
* The use of any investigational drug within 30 days prior to Visit 1. No investigational products are permitted for use during the conduct of this study
* Presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol or sucralose (Splenda® brand sweetener)
* Respiratory tract infections within two weeks prior to Visit 1.
* Subjects with significant pulmonary disease including asthma. Subjects with intermittent asthma who only require short-acting inhaled bronchodilators are eligible for enrollment. Asthma (with the exception of intermittent asthma). Subjects with intermittent asthma who only require short-acting inhaled bronchodilators (not more often than twice per week) and who do not have nocturnal awakening as a result of asthma are eligible for enrollment
* Chronic obstructive sleep apnea syndrome (clinical diagnosis)
* Existence of any surgical or medical condition, which in the opinion of the investigator or sponsor's medical monitor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug or that might significantly affect the subject's ability to complete this trial
* Clinically relevant abnormal physical findings or laboratory results which, in the opinion of the investigator, would interfere with the objectives -- Family members of research center or private practice personnel who are directly involved in this study are excluded
* Members of the same family cannot enroll in the study at the same time.
* Subjects who have used medications or therapies that could interfere with safety evaluations (see Section 4.0)
* Any behavioral condition which could affect subject's ability to accurately report symptoms to the caregiver such as developmental delay, attention deficit disorder, and autism

Primary outcomes:
measure: Safety
timeFrame: one month of treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Clinical Research Center of Alabama,LLC
state: Alabama
city: Little Rock
country: United States
facility: Little Rock Allergy and Asthma Clinical research Center
state: Alaska
city: Costa Mesa
country: United States
facility: West Coast Clinical Trials
state: California
city: Mission Viejo
country: United States
facility: Southern California Research
state: California
city: Colorado Springs
country: United States
facility: Storms Clinical Research Institute
state: Colorado
city: Normal
country: United States
facility: Sneeze, Wheeze and Itch Associates
state: Illinois
city: Oklahoma City
country: United States
facility: Allergy, Asthma & Clinical Research Center
state: Oklahoma
city: Charleston
country: United States
facility: National Allergy, Asthna & Urticaria Centers of Charleston Pa
state: Pennsylvania
city: Dallas
country: United States
facility: Texas Allergy Research Center
state: Texas
city: New Braunfels
country: United States
facility: Central Texas Health Research
state: Texas
city: San Antonio
country: United States
facility: Paul H Ratner,MD
state: Texas
city: San Antonio
country: United States
facility: Live Oak Allergy and Asthma Clinic
state: Texas
city: Waco
country: United States
facility: Allergy and Asthma Center
state: Texas
city: Waco
country: United States
facility: Pediatric Allergy,Asthma and Immunology/Allergy& Asthma care of Waco
state: Texas
Study officials:
References: